Page 178 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.1. Descriptive characteristics of the epidemiologic studies considered relevant to KQ1 (continued)
Author Database Start End year Sample size Eligibility criteria
Year year
uid
88
Gross SEER- 1992 2002 82,328 (74,288 Patients with early stage prostate cancer who received RP, BT, or EBRT;
2008 Medicare white, 8040 black) blacks and whites only. Data on treatment patterns were reported only among
18181101 patients with localized disease.
89
Welch SEER- 1993 2001 10,429 Men with a claim for a needle biopsy of the prostate during the study period
2007 Medicare [men with a needle were included, base on the 5% Medicare Part B sample. Men not aged ≥65
17848671 biopsy of the yr at the start of each calendar year, not entitled to Part B for the entire year,
prostate] or enrolled in risk-contract managed care plans were excluded. Men who had
a concomitant transurethral resection of the prostate or who had a prior
prostate cancer diagnosis were also excluded.
62
Carpenter SEER- 1994 2002 18,067 Black and White men, aged ≥65 yr, diagnosed with prostate cancer in the
2010 Medicare following 8 SEER registries: Atlanta, Connecticut, Detroit, Rural Georgia, Los
20333462 Angeles, San Francisco-Oakland, San Jose, Seattle-Puget Sound. Included
patients had to have known prostate cancer stage, no prior or concurrent
cancers, no gaps in Medicare coverage for 3 yr prior to diagnosis, and no
HMO coverage from enrollment to diagnosis.
63
Mullins SEER- 1998 2002 42,318 Prostate cancer patients with Medicare, aged ≥65 yr. Excluded men with
2010 Medicare [13,447 in 1998; unknown mo of diagnosis, <65 yr old at time of diagnosis, races other than
20163844 28,871 in 2002] non-Hispanic White, AA, and White Hispanic, missing Census Tract
information.
64
Kindrick CaPSURE 1989 1997 3557 Biopsy-confirmed prostate adenocarcinoma. Excluded patients with a missing
1998 date of diagnosis or those for whom no initial treatment was recorded.
9817332 Patients included in CaPSURE between 1995-97 were included, including
non-incident cases (those diagnosed since 1989).
65
Cooperberg CaPSURE 1989 2001 4966 Excluded those diagnosed before 1989 and those with missing information on
2002 primary treatment or clinical staging.
12131295
4
Cooperberg CaPSURE 1989 2002 6290 Unselected men with biopsy-proven prostate adenocarcinoma. Excluded
2003 those with missing data on PSA, T stage or multiple parameters.
14610406
5
Cooperberg CaPSURE 1989 2001 3439 Patients who received RP, EBRT, BT, PADT or WW as primary therapy.
2003 Patients with incomplete clinical staging information, those with missing data
12837834 on treatment and those receiving cryotherapy as primary treatment were
excluded.

C-7